| Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections. | |
| | |
MedLine Citation:
|
PMID: 17959359 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The overall expected coverage for tigecycline and selected antimicrobial regimens based upon prevailing susceptibility rates was evaluated for the empirical therapy of complicated skin and skin-structure infections (cSSSIs). Consecutive, non-duplicate bacterial isolates collected from 2000-2005 from patients with documented cSSSI in 57 medical centres located in the USA (38 centres), France (6 centres), Germany (7 centres), Italy (3 centres) and Spain (3 centres) were used to evaluate the frequency of pathogen occurrence and susceptibility rates of select parenteral antimicrobials (SENTRY Program). By applying pathogen-specific susceptibility rates to the frequency of pathogen occurrence in each country, the overall expected coverage for each treatment regimen was measured. The most frequently isolated pathogens were Staphylococcus aureus (33.3-49.9%), Pseudomonas aeruginosa (8.3-17.2%), Escherichia coli (6.6-13.9%) and enterococci (4.1-8.8%). Tigecycline was highly active against the most common pathogens, except for P. aeruginosa and Proteus mirabilis. The highest overall expected empirical coverage was obtained with combination therapy regimens, including vancomycin plus either imipenem (94.4-99.3%) or piperacillin/tazobactam (92.5-98.2%). Among the monotherapy regimens evaluated, tigecycline provided the highest overall expected coverage in the USA (90.6%), France (89.9%) and Italy (83.3%), whilst piperacillin/tazobactam showed the highest expected coverage in Germany (93.1%) and imipenem in Spain (87.7%). Our results suggest that tigecycline represents a viable additional option for the empirical treatment of cSSSI in these countries. |
| | |
Authors:
|
Helio S Sader; Rajiv Mallick; Andreas Kuznik; Thomas R Fritsche; Ronald N Jones |
Related Documents
:
|
21896419 - [proposed recommendations for the practical use of internal quality controls (iqc) in a... 21993709 - What information do cancer genetic counselees prioritize? 15718709 - The virtual pediatric standardized patient application: formative evaluation findings. 22270799 - On markets and morals-(re-)establishing independent decision making in healthcare. 15223169 - Predictive value of hysteroscopic examination in intrauterine abnormalities. 1135649 - An evaluation of the management of hypertensive patients. 7538519 - An overview of current pharmacotherapy in perennial rhinitis. 17892239 - Social work roles and activities regarding psychiatric medication: results of a nationa... 1549319 - Medical staff privileges for ethics consultants: an institutional model. |
Publication Detail:
|
Type: Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't Date: 2007-10-23 |
Journal Detail:
|
Title: International journal of antimicrobial agents Volume: 30 ISSN: 0924-8579 ISO Abbreviation: Int. J. Antimicrob. Agents Publication Date: 2007 Dec |
Date Detail:
|
Created Date: 2007-11-12 Completed Date: 2008-01-29 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9111860 Medline TA: Int J Antimicrob Agents Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 514-20 Citation Subset: IM |
Affiliation:
|
JMI Laboratories, 345 Beaver Kreek Centre, Suite A, North Liberty, IA 52317, USA. helio-sader@jmilabs.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anti-Bacterial Agents*
/
pharmacology,
therapeutic use Drug Resistance, Bacterial Europe / epidemiology Gram-Negative Bacteria* / drug effects, isolation & purification Gram-Positive Cocci* / drug effects, isolation & purification Humans Microbial Sensitivity Tests Minocycline / analogs & derivatives*, pharmacology, therapeutic use Models, Biological* Population Surveillance / methods Prevalence Skin Diseases, Bacterial* / drug therapy, epidemiology, microbiology Soft Tissue Infections* / drug therapy, epidemiology, microbiology Treatment Outcome United States / epidemiology |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Bacterial Agents; 0/tigecycline; 10118-90-8/Minocycline |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Spanish version of the Screen for Cognitive Impairment in Psychiatry (SCIP-S): psychometric properti...
Next Document: Relationship between susceptibility to antimicrobials and virulence factors in paediatric Escherichi...